Mylan CEO believes EpiPen price ‘fair’

Published



Mylan CEO Heather Bresch delivered a defiant performance before a group of hostile lawmakers upset over the company’s EpiPen’s price hike, as she called the current $600 price tag “fair.”

Bresch refused to apologize before the House Oversight and Government Reform Committee Wednesday for raising the price by more than 400 percent since the generic drug maker acquired the allergy treatment in 2007. She said in her opening statement that Mylan regrets not anticipating the magnitude of a “growing minority of patients who may have ended up paying the full [wholesale acquisition cost] price and more.”

Trusted reporting.Unlimited access.

Subscribe for full access to Washington Examiner coverage, expert political analysis, and subscriber-only journalism.

Get Unlimited Access

Already a member? Log in

Cancel anytime.